The FDA has taken a clear position with Project Optimus in shifting toward more progressive tailored approaches while rejecting antiquated study designs to evolve clinical trial strategies to better align with newer drug classes.
Sirj Goswami, PhD, and Jason Rizzo, MBA
Advertisement
Articles by Sirj Goswami, PhD, and Jason Rizzo, MBA
Advertisement
Latest Updated Articles
Artificial Intelligence Drives Industry Response to Project OptimusFebruary 27th 2024
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-World Evidence Is Moving Upstream: Is the Data Infrastructure Ready?
2
The Data Inputs That Matter Most When Pressure-Testing a Protocol's Feasibility
3
Where AI Leads in Trial Design—and Where Humans Still Need To
4
ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval
5